Peptide Pro Solutions asks what stays solved

Tesamorelin’s six-month scan findings

In a six-month trial, 50 adults receiving HIV treatment had scans to measure fat around their abdominal organs and in their livers. Tesamorelin produced a difference of -42 square centimeters in visceral-fat change compared with placebo, and liver fat fell too. Visceral means the fat tucked around the organs. That is a more particular result than a change on a bathroom scale.

The follow-up question comes from a different study. In the 52-week tesamorelin program, the reduction in visceral fat was sustained at -18% during continued treatment. When participants stopped treatment, that fat accumulated again.

The scan finding still earns my enthusiasm after that reversal. A useful treatment can require continuing work. But “solutions” sounds wonderfully final, and these papers describe something more demanding: a benefit maintained during treatment, with the original problem returning afterward.

Continuing treatment and stopping treatment gave different answers in the longer tesamorelin study. Both deserve space beside the reduction.

A solution to which problem?

I credit tesamorelin’s trials with answering a particular clinical question. Its United States approval in 2010 concerns excess abdominal fat in adults with HIV-associated lipodystrophy, abnormal fat distribution associated with HIV treatment. General weight loss, slowing aging and improving memory extend beyond that approval.

The plural in Peptide Pro Solutions starts to earn its place here. Getting a bowel moving after surgery, reducing fat around organs and raising a blood hormone are separate tasks. A compound can succeed at one measurement while leaving another question completely open.

Ipamorelin’s trial in 114 adults after bowel resection missed its primary endpoint, the planned test of benefit. CJC-1295 with ipamorelin has no controlled human trial of the combination. The orthopaedic review describing stronger muscle contractions in steroid-treated mice gives that pair an animal finding; human sleep and recovery claims still await a clinical test.

A single ladder from “milder” to “stronger” peptides leaves me unconvinced. The destination changes between papers.

Time spent in blood

CJC-1295 with DAC was engineered to stay around: its attachment to albumin, a circulating blood protein, prolonged exposure in rat experiments on the albumin-bound peptide. In healthy adults given CJC-1295 alone, growth hormone rose two- to ten-fold for at least six days, and IGF-1, the growth-related hormone made mainly by the liver, remained elevated for nine to eleven days.

Ipamorelin’s intravenous study in healthy men instead described a growth-hormone pulse peaking at about 40 minutes and an approximately two-hour terminal half-life. Half-life describes how quickly blood concentration falls during elimination.

Prolonging exposure is a chemical achievement I can appreciate. For a person’s health, the next questions concern the benefit, the harms and how long both were observed. The clinical review of growth hormone secretagogues identifies blood sugar as a concern and asks for longer data on cancer and mortality.

The three investigations

The tesamorelin page stays with abdominal fat, liver fat and the return after discontinuation. Ipamorelin follows a selective hormone response into a clinical test that disappointed. The CJC-1295/ipamorelin page examines what adding a second signal leaves unmeasured.

For a compact comparison, match each compound to its tested problem. The FAQ covers children, prolonged stimulation, endometriosis and the proposal to combine all three. These pages provide research information; treatment decisions require an assessment of the individual.